ALS drug edaravone shows promise in slowing disease progression
NCT ID NCT00330681
First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This Phase 3 trial tested the drug edaravone (MCI-186) in 206 people with ALS. Participants received daily intravenous infusions for 14 days, followed by a rest period, repeated over 24 weeks. The goal was to see if edaravone could slow the decline in physical function compared to a placebo. The study measured changes in the ALS Functional Rating Scale (ALSFRS-R) and monitored safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Edaravone (also called MCI-186 or Radicut), given as an intravenous infusion
- What this could lead to
- If successful, this could provide a treatment option that slows the progression of ALS, helping patients maintain function for longer.
- What could go wrong
- This is a completed Phase 3 trial, but results may not apply to all ALS patients. The benefit may be modest, and side effects from the infusion are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Blood test may slash ALS diagnosis time from months to days
- Custom gene silencer takes aim at a rare form of ALS
- Could a gentle brain ZAP help ALS patients breathe easier?